Inferior survival for patients with chronic lymphocytic leukemia who progress with lymphadenopathy
Some patients with BTK mutations could benefit from treatment changes at earlier stages.
Many clinical and ethical factors influence whether preemptive transplant would be beneficial for patients genetically predisposed to acute myeloid leukemia.
An alternative measure of relapse risk is needed in patients for whom no polymerase chain reaction marker is available.
Platelet aggregation and platelet activation were both independently associated with bleeding risk.
The majority of patients achieved complete remission with or without incomplete count recovery after receiving 12 cycles of combination therapy.
The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.
The increased risk for infection seen in pediatric patients receiving transplants from unrelated donors could be a result of intensified graft-versus-host disease prophylaxis.
Rates of leukemia-free and overall survival were 20% and 30%, respectively, at 2 years and 12% and 14%, respectively, at 5 years.
The researchers examined 37 recurrently mutated genes in AML using next-generation sequencing.
Researchers evaluated response rates to azacitidine and decitabine in patients with chronic myelomonocytic leukemia according to various sets of response criteria.
Results from ongoing trials suggest targeted therapy may improve survival outcomes in acute myeloid leukemia, but further research is needed.
A substantial proportion of patients who received bosutinib achieved major cytogenetic response and molecular response within 1 year.
Intensity of induction chemotherapy was associated with measurable residual disease negativity but not overall survival.
Patients receiving ibrutinib had an overall response rate of 8% and median progression-free survival of 44.1 months.
Among 126 patients who entered treatment-free remission, 58 remained in remission at 192 weeks.
Researchers sought to expand upon what is known about smoking status and AML diagnosis and understand more about how smoking affects treatment outcomes.
A significantly greater proportion of patients in the flumatinib group had a complete molecular response at 12 months compared with in the imatinib group.
The e13a2 transcript was expressed more frequently in men and pediatric patients.
Patients receiving idelalisib experienced longer median overall survival compared with patients receiving placebo.
The FDA has approved Venclexta in combination with Gazyva for the treatment of patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Many CML patients on TKI treatment report muscle complaints, but there has been little work to find out why. A new study sought to find out more about the nature of these complaints and to undercover a biological mechanism to explain them.
Twitter is increasingly being used by oncologists as a tool to communicate advancements in in the treatment of cancer. What could go wrong?
Propensity score analysis showed that patients in the inotuzumab ozogamicin arm experienced significantly longer event-free and overall survival.
What is the role of the clinician in managing financial toxicity?
Advances in treatment options for acute myeloid leukemia may replace currently accepted induction regimens as the standard of care.
High risk for tumor lysis syndrome and creatinine clearance below 80 mL/min were associated with tumor lysis syndrome development.
The FDA has expanded the indication for Tibsovo to include treatment of newly diagnosed acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
Bruce Levine, PhD, explains why targeting multiple antigens simultaneously may be the most promising approach for adoptive cell therapies such as CAR-T.
Researchers assessed 13,276 patients with chronic myeloid leukemia to characterize the incidence and types of second malignancies in this patient population.
Patients enrolled in a phase 1 trial receiving ibrutinib demonstrated augmented ex vivo CAR T-cell expansion.
Your patients may have questions about leukemia. Help them better understand the condition by sharing this article with them.
Patients carrying the -21M variant of HLA-B demonstrated more favorable clinical outcomes than patients carrying the -21T variant.
In this review, researchers discussed strategies for identifying and treating infection in patients undergoing intensive chemotherapy.
The presence of measurable residual disease may be a reliable predictor of relapse in patients with acute myeloid leukemia.
The combination of antithrombin activity and fibrinogen levels demonstrated optimal accuracy in detecting subtherapeutic L-asparaginase levels.
Relapse risk increased with cumulative granulocyte colony-stimulating factor dosage but appeared to level out at approximately 75 mg/kg to 100 mg/kg.
Integrating mutation-specific data across repositories and portals may lead to novel therapeutically actionable insights for acute myeloid leukemia.
Variability in minimal residual disease measurement techniques inhibits the ability to compare data across laboratories and clinical trials.
Treatment for lymphoblastic lymphomas may result in high morbidity and poor prognosis, highlighting the need for novel targeted therapeutic approaches.
Patients with rapid early response demonstrated increased event-free and overall survival when receiving augmented postinduction intensification regimens.
With advances in cancer research and treatments, patients with acute lymphoblastic leukemia (ALL) can enjoy longer lives and treatment can continue long after initial hospital admission and into the outpatient setting.1,2 Parents of children with leukemia often find themselves serving as direct caregivers for their children, an important role that may require them to receive…
Specific cytogenetic abnormalities are associated with patient outcomes after allogeneic hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML) and may have prognostic value, according to a study published in Leukemia. A multinational research team conducted a retrospective analysis of clinical outcomes of patients with AML undergoing allogeneic HSCT while taking into account recurring…
Discontinuing antibacterial therapy in neutropenic patients with acute myeloid leukemia did not lead to excessive mortality or severe infections.
CAR T therapy has emerged in recent years as a feasible treatment for patients with chronic lymphocytic leukemia, but there are still many unanswered questions.
An expert panel from the European LeukemiaNet discussed optimal treatment strategies for patients with acute promyelocytic leukemia.
Researchers classified 49 single-agent and 13 multiple-agent chemotherapy regimens by severity of emetogenicity.
Immune checkpoint inhibitor therapy is associated with improved outcomes but it may also lead to serious adverse effects.
There is a pressing need to develop novel therapeutic strategies for patients with myelodysplastic syndrome who are ineligible for transplantation.
Researchers measured levels of glucagon-like peptide-1 and C-reactive protein to determine their value as predictive biomarkers of toxicity.
GVHD prophylaxis including anti-T-lymphocyte globulin was associated with improved survival and quality of life.